Advanced Magnetics' Combidex "Approvable" Letter Requests More Efficacy Data

The decision follows the Oncologic Drugs Advisory Committee vote that current data do not support approval of the imaging agent for the proposed indication. FDA suggested that the data be "limited to a well-defined population of specific cancer types," the company says.